Equities research analysts expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report earnings per share of ($1.80) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings. The highest EPS estimate is ($1.57) and the lowest is ($1.95). Alnylam Pharmaceuticals reported earnings of ($1.06) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 69.8%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($6.66) per share for the current year, with EPS estimates ranging from ($6.96) to ($6.11). For the next financial year, analysts forecast that the company will report earnings of ($7.41) per share, with EPS estimates ranging from ($8.74) to ($6.37). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.11. The business had revenue of $29.91 million for the quarter, compared to the consensus estimate of $16.96 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The firm’s quarterly revenue was up 87.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.07) earnings per share.
Several equities research analysts have weighed in on ALNY shares. Needham & Company LLC restated a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 13th. ValuEngine cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 21st. Cowen restated a “buy” rating and set a $157.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 2nd. BidaskClub cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 2nd. Finally, BMO Capital Markets cut their target price on Alnylam Pharmaceuticals from $127.00 to $125.00 and set an “outperform” rating for the company in a research note on Monday, August 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $144.17.
NASDAQ:ALNY traded down $1.65 during trading hours on Wednesday, reaching $81.26. 451,200 shares of the company were exchanged, compared to its average volume of 904,516. The company has a market capitalization of $8.81 billion, a P/E ratio of -14.99 and a beta of 2.56. Alnylam Pharmaceuticals has a 1-year low of $78.85 and a 1-year high of $153.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22.
In other news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,916 shares in the company, valued at approximately $229,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 50,000 shares of the stock in a transaction on Wednesday, July 25th. The shares were sold at an average price of $105.39, for a total value of $5,269,500.00. Following the completion of the transaction, the chief executive officer now owns 201,297 shares of the company’s stock, valued at $21,214,690.83. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in ALNY. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $137,000. Mutual of America Capital Management LLC raised its position in Alnylam Pharmaceuticals by 98.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 960 shares during the last quarter. IPG Investment Advisors LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $217,000. First Republic Investment Management Inc. bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $230,000. Finally, Riverhead Capital Management LLC raised its position in Alnylam Pharmaceuticals by 195.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares during the last quarter. 93.41% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Read More: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.